Genticel aims to prevent Cancer caused by the Human Papillomavirus

02/06/2015 - 2 minutes

Genticel is a step closer to prevent cancer caused by the human papillomavirus (HPV). The French biotech announced positive results of GTL002’s preclinical in vivo proof of concept, Genticel’s multivalent HPV therapeutic vaccine candidate based on the company’s versatile Vaxiclase platform.

Vaxiclase is a technology platform that can be used with many antigens in several indications. Last February, Genticel signed a first licensing agreement with the Serum Institute of India, the world’s largest producer of vaccine doses, to evaluate Vaxiclase to produce multivalent vaccines against Pertussis, the whooping cough disease. Genticel received up to €51M in upfront and milestones payments, plus royalties on sales.

The company is spending the cash well, developing its new candidate, GTL002. The proof of concept data of the drug demonstrated that an in vivo immune response was induced against each of the six HPV-derived proteins present in the therapeutic vaccine. In addition, in vivo therapeutic efficacy has been proven after tumor eradication in the most widely used and broadly accepted reference model.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member